International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 4 , Pages 973-977 , 15 March 2010

Imaging Primary Lung Cancers in Mice to Study Radiation Biology

  • David G. Kirsch, M.D., Ph.D.

      Affiliations

    • The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • Departments of Radiation Oncology and Pharmacology & Cancer Biology, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests to: David G. Kirsch, Box 91006, Duke University Medical Center, Durham, NC 27708. Tel: (919) 681-8586; Fax: (919) 681-1867
    • ,
  • Jan Grimm, M.D.

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA
    • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
    • Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • Alexander R. Guimaraes, M.D., Ph.D.

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA
    • Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    • Department of Radiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Gregory R. Wojtkiewicz, M.S.

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA
    • ,
  • Bradford A. Perez, B.S.

      Affiliations

    • Departments of Radiation Oncology and Pharmacology & Cancer Biology, Duke University Medical Center, Durham, NC
    • ,
  • Philip M. Santiago, B.S.

      Affiliations

    • The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
    • ,
  • Nikolas K. Anthony, R.T.T.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Thomas Forbes, R.T.T.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Karen Doppke, M.S.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Ralph Weissleder, M.D., Ph.D.

      Affiliations

    • Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA
    • Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    • Department of Radiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Tyler Jacks, Ph.D.

      Affiliations

    • The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
    • Howard Hughes Medical Institute, Chevy Chase, MD

Received 8 September 2009 ,Revised 10 November 2009 ,Accepted 10 November 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  2. Jemal A, Travis WD, Tarone RE, et al. Lung cancer rates convergence in young men and women in the United States: Analysis by birth cohort and histologic type. Int J Cancer. 2003;105:101–107
  3. Taghian AG, Suit HD. Animal systems for translational research in radiation oncology. Acta Oncol. 1999;38:829–838
  4. Sharpless NE, Depinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5:741–754
  5. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–1159
  6. Shinohara ET, Geng L, Tan J, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 2005;65:4987–4992
  7. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661–665
  8. Izumi Y, di Tomaso E, Hooper A, et al. Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Res. 2003;63:747–751
  9. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–3248
  10. Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280–10288
  11. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–1075
  12. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005;37:48–55
  13. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–682
  14. Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: Stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:1235–1242

 Supported by the Howard Hughes Medical Institute (T.J., B.A.P.), American Cancer Society Institutional Research Grant, KO8 CA 114176 (D.G.K.), P50 CA86355 (D.G.K., R.W.), R24 CA92782 (R.W.), U24 CA 092782 (R.W., T.J.), NCI grant 5-U01-CA84306 (T.J.), partially by Cancer Center Support (core) grant P30-CA14051 from the NCI (T.J.) and by a medical student seed grant from the RSNA (B.A.P.). Dr. Jacks is the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar.

 Conflict of interest: none.

PII: S0360-3016(09)03604-9

doi: 10.1016/j.ijrobp.2009.11.038

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 4 , Pages 973-977 , 15 March 2010

Article Tools

* Image Usage & Resolution